MongoDB, Inc. (M1DB34)
B3 Stock Exchange · Brazil · prices in BRL · close of 27 Oct 2026
Key indicators
| Last close | BRL 103.80 |
|---|---|
| 52-week range | 56.12 – 122.51 |
| Return, 1 month / 3 months | −4.1% / +30.4% |
| Return, 1 year / 3 years | +14.1% / +24.4% |
| Trend | Uptrend |
| RSI (14) | 57 |
| Volatility (1 year) | 74.3% |
| Worst drawdown (1 year) | -54.2% |
| Average daily value traded | 0.06M BRL |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
MongoDB, Inc. provides database software built around a document-oriented data model that stores information in flexible, JSON-like records. Its main offering is the MongoDB database, available as a self-managed product and as a hosted cloud service, which developers use to build and run applications. Customers range from individual developers and startups to large enterprises across many industries. The company is based in the United States and serves users around the world.
MongoDB, Inc. is represented on the B3 Stock Exchange in Brazil by a Brazilian depositary receipt (BDR) under the code M1DB34, with its price quoted in Brazilian reais (BRL). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
MongoDB, Inc. (M1DB34) trades on the B3 Stock Exchange in Brazil. It last closed at BRL 103.80 on 27 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 534 of 1,455 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 14.1% and over the last three months it rose 30.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on B3 Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 73 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 19.1% | ||
| From 52-week high | -15.3% | ||
| Momentum | 84 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 30.4% | ||
| 6-month return | 57.3% | ||
| 12-month return, skipping the last month | 19.0% | ||
| Stability (higher is calmer) | 13 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 74.3% | ||
| Worst drawdown, 1 year (smaller is calmer) | -54.2% | ||
| Liquidity | 54 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.06M BRL | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +13.7% |
|---|---|
| 1 month | −4.1% |
| 3 months | +30.4% |
| 6 months | +57.3% |
| 1 year | +14.1% |
| 3 years | +24.4% |
| 5 years | −28.6% |
Signals
| 50-day / 200-day average | 99.26 / 87.18 |
|---|---|
| Golden / death cross (60 days) | Golden, 55 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.81 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on B3 Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.